Could accelerated aging explain the excess mortality in patients with seropositive rheumatoid arthritis?

Cynthia Crowson, Kimberly P. Liang, Terry M Therneau, Hilal D Maradit Kremers, Sherine E. Gabriel

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective. To determine whether the mortality pattern in patients with seropositive rheumatoid arthritis (RA) is consistent with the concept of accelerated aging, by comparing the observed mortality rates in patients with RA with the age-accelerated mortality rates from the general population. Methods. A population-based inception cohort of patients with seropositive RA (according to the American College of Rheumatology 1987 criteria) was assembled and followed up for vital status until July 1, 2008. The expected mortality rate was obtained by applying the death rates from the general population to the age, sex, and calendar year distribution of the RA population. The observed mortality was estimated using Kaplan-Meier methods. Acceleration factors for the expected mortality were estimated in accelerated failure time models. Results. A total of 755 patients with seropositive RA (mean age 55.6 years, 69% women) were followed up for a mean of 12.5 years, during which 315 patients died. The expected median survival was age 82.4 years, whereas the median survival of the RA patients was age 76.7 years. Results of statistical modeling suggested that, in terms of mortality rates, patients with RA were effectively 2 years older than actual age at RA incidence, and thereafter the patients underwent 11.4 effective years of aging for each 10 years of calendar time. Conclusion. The overall observed mortality experience of patients with seropositive RA is consistent with the hypothesis of accelerated aging. The causes of accelerated aging in RA deserve further investigation.

Original languageEnglish (US)
Pages (from-to)378-382
Number of pages5
JournalArthritis and Rheumatism
Volume62
Issue number2
DOIs
StatePublished - Feb 2010

Fingerprint

Rheumatoid Arthritis
Mortality
Population
Survival
Incidence

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Rheumatology
  • Pharmacology (medical)

Cite this

Could accelerated aging explain the excess mortality in patients with seropositive rheumatoid arthritis? / Crowson, Cynthia; Liang, Kimberly P.; Therneau, Terry M; Maradit Kremers, Hilal D; Gabriel, Sherine E.

In: Arthritis and Rheumatism, Vol. 62, No. 2, 02.2010, p. 378-382.

Research output: Contribution to journalArticle

@article{b3fba766b0124565b70bb1afbd2202b7,
title = "Could accelerated aging explain the excess mortality in patients with seropositive rheumatoid arthritis?",
abstract = "Objective. To determine whether the mortality pattern in patients with seropositive rheumatoid arthritis (RA) is consistent with the concept of accelerated aging, by comparing the observed mortality rates in patients with RA with the age-accelerated mortality rates from the general population. Methods. A population-based inception cohort of patients with seropositive RA (according to the American College of Rheumatology 1987 criteria) was assembled and followed up for vital status until July 1, 2008. The expected mortality rate was obtained by applying the death rates from the general population to the age, sex, and calendar year distribution of the RA population. The observed mortality was estimated using Kaplan-Meier methods. Acceleration factors for the expected mortality were estimated in accelerated failure time models. Results. A total of 755 patients with seropositive RA (mean age 55.6 years, 69{\%} women) were followed up for a mean of 12.5 years, during which 315 patients died. The expected median survival was age 82.4 years, whereas the median survival of the RA patients was age 76.7 years. Results of statistical modeling suggested that, in terms of mortality rates, patients with RA were effectively 2 years older than actual age at RA incidence, and thereafter the patients underwent 11.4 effective years of aging for each 10 years of calendar time. Conclusion. The overall observed mortality experience of patients with seropositive RA is consistent with the hypothesis of accelerated aging. The causes of accelerated aging in RA deserve further investigation.",
author = "Cynthia Crowson and Liang, {Kimberly P.} and Therneau, {Terry M} and {Maradit Kremers}, {Hilal D} and Gabriel, {Sherine E.}",
year = "2010",
month = "2",
doi = "10.1002/art.27194",
language = "English (US)",
volume = "62",
pages = "378--382",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Could accelerated aging explain the excess mortality in patients with seropositive rheumatoid arthritis?

AU - Crowson, Cynthia

AU - Liang, Kimberly P.

AU - Therneau, Terry M

AU - Maradit Kremers, Hilal D

AU - Gabriel, Sherine E.

PY - 2010/2

Y1 - 2010/2

N2 - Objective. To determine whether the mortality pattern in patients with seropositive rheumatoid arthritis (RA) is consistent with the concept of accelerated aging, by comparing the observed mortality rates in patients with RA with the age-accelerated mortality rates from the general population. Methods. A population-based inception cohort of patients with seropositive RA (according to the American College of Rheumatology 1987 criteria) was assembled and followed up for vital status until July 1, 2008. The expected mortality rate was obtained by applying the death rates from the general population to the age, sex, and calendar year distribution of the RA population. The observed mortality was estimated using Kaplan-Meier methods. Acceleration factors for the expected mortality were estimated in accelerated failure time models. Results. A total of 755 patients with seropositive RA (mean age 55.6 years, 69% women) were followed up for a mean of 12.5 years, during which 315 patients died. The expected median survival was age 82.4 years, whereas the median survival of the RA patients was age 76.7 years. Results of statistical modeling suggested that, in terms of mortality rates, patients with RA were effectively 2 years older than actual age at RA incidence, and thereafter the patients underwent 11.4 effective years of aging for each 10 years of calendar time. Conclusion. The overall observed mortality experience of patients with seropositive RA is consistent with the hypothesis of accelerated aging. The causes of accelerated aging in RA deserve further investigation.

AB - Objective. To determine whether the mortality pattern in patients with seropositive rheumatoid arthritis (RA) is consistent with the concept of accelerated aging, by comparing the observed mortality rates in patients with RA with the age-accelerated mortality rates from the general population. Methods. A population-based inception cohort of patients with seropositive RA (according to the American College of Rheumatology 1987 criteria) was assembled and followed up for vital status until July 1, 2008. The expected mortality rate was obtained by applying the death rates from the general population to the age, sex, and calendar year distribution of the RA population. The observed mortality was estimated using Kaplan-Meier methods. Acceleration factors for the expected mortality were estimated in accelerated failure time models. Results. A total of 755 patients with seropositive RA (mean age 55.6 years, 69% women) were followed up for a mean of 12.5 years, during which 315 patients died. The expected median survival was age 82.4 years, whereas the median survival of the RA patients was age 76.7 years. Results of statistical modeling suggested that, in terms of mortality rates, patients with RA were effectively 2 years older than actual age at RA incidence, and thereafter the patients underwent 11.4 effective years of aging for each 10 years of calendar time. Conclusion. The overall observed mortality experience of patients with seropositive RA is consistent with the hypothesis of accelerated aging. The causes of accelerated aging in RA deserve further investigation.

UR - http://www.scopus.com/inward/record.url?scp=75749094407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749094407&partnerID=8YFLogxK

U2 - 10.1002/art.27194

DO - 10.1002/art.27194

M3 - Article

VL - 62

SP - 378

EP - 382

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 2

ER -